In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Silence Therapeutics, with a price target of $75.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Patrick Trucchio has given his Buy rating due to a combination of factors, primarily focusing on Silence Therapeutics’ accelerating momentum in their RNA interference pipeline. The company has shown disciplined execution across its clinical and platform programs, highlighted by the completion of enrollment in the Phase 2 SANRECO trial for divesiran, which is expected to yield top-line data by the third quarter of 2026.
Additionally, Silence Therapeutics’ zerlasiran program is fully prepared for Phase 3, with strong regulatory alignment and ongoing partnership discussions to support a cardiovascular outcomes trial. The company’s early-stage pipeline is progressing well, including advancements in the AstraZeneca-partnered SLN312 program and promising research in extra-hepatic delivery. With a robust cash position and financial runway into 2028, Silence is well-capitalized to advance its clinical programs and achieve key milestones, supporting Trucchio’s optimistic outlook and the reiterated Buy rating with a $75 price target.
According to TipRanks, Trucchio is a top 100 analyst with an average return of 34.8% and a 52.26% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Aligos Therapeutics, Precision BioSciences, and Altimmune.